FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 4, 2010, Pages 436-441

  Lopci, E ^a   Santi, I ^a   Tani, M ^a   Maffione, A M ^a   Montini, G ^a   Castellucci, P ^a   Stefoni, V ^a   Rubello, D ^b   Fonti, C ^a   Zinzani, P ^a   Fanti, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Ibritumomab tiuxetan; Lymphoma, follicular; Lymphoma, non hodgkin; Positron emission tomography; Radioimmunotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMAGING SYSTEM; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; EVALUATION; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 78650675907     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Armitage JO, Weisenburger DD. New approach to classifying nonHodgkins lymphomas: clinical features of the major histologic subtypes. Non-Hodgkins Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95.
2. Bartlett NL, Witzig T E, Gordon L, Beck T, Fehrenbacher L, Kornmehl E et al. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. ASCO Annual Meeting 2002.
3. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens leukemias and lymphomas: a model of human B cell differenciation. Blood 1984;63:1424-33.
4. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn RW et al. Long-term responses in patients with recurring or refractory b-cell Non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804-10.
5. Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002;2:485-93.
6. Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F et al. EANM procedure guideline for radioimmunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging 2007; 34:616-22.
7. Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cel nonHodgkin's lymphoma. Expert Rev Anticancer Ther 2004;4:18-26.
8. Wagner HNJr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, FinkBennett DM et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled antiCD20 monoclonal antibody. J Nucl Med 2002;43:267-72.
9. Weigert O, Illidge T, Hiddemann W, Dreyling M. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer 2006;1074:686-95.
10. JoyceJM, Degirmenci B, Jacobs S, McCook B, Avril N. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy. Clin Nucl Med 2005;30:564-8.
11. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomised controlled trias of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus riruximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
12. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99: 4336-42.
13. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000;27: 1564-78.
14. Talbot JN, Haioun C, Rain JD:[18F]-FDG positron imaging in clinical management of lymphoma patients. Clinical Reviews in Oncology/Ematology 2001;38:193-221.
15. Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008;80:369-80.
16. Wöhrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K et al. 18F-fiuoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780-4.
17. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade nonHodgkin's lymphoma (NHL). Ann Oncol 2001;12:825-30.
18. Zinzani PL, Musuraca G, Alinari L, Fanti S, Táni M, Stefoni V et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007;7:291-5.
19. T Papajik, V. Prochazka, L. Raida, Z. Kubova, M. Myslivecek, J. Drymlova et al. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab Tiuxetan. Case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007;151:109-12.
20. Ulaner GA, Colletti PM, Conti PS. B-cell Non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy-initial experience. Radiology 2008;246:895-902.
21. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(?) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803.
22. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
23. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.
24. Zinzani PL, d'Amore F, Bombardieri E, Brammer C, Codina JG, Midge T et al. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Eur J Cancer 2008;44: 366-73.
25. Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract]. Proc Am Soc Clin Oncol 2004;23:560.
26. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47: 629-36.
27. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M et al. Durable responses after ibritumomab tiuxetan radioimmunohterapy for CD20+ B-cell lymphoma: long-tem follow-up of phase II study. Blood 2004;103:4429-31.
28. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE et al. Response assessment of aggressive nonHodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fiuorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-61.